Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BridgeBio Pharma, Inc. - Common Stock (NQ: BBIO )

26.49 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1
Open 26.49
Bid (Size) 24.89 (1)
Ask (Size) 27.00 (1)
Prev. Close 26.49
Today's Range 26.49 - 26.49
52wk Range 21.62 - 44.32
Shares Outstanding 160,500,999
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga

Performance

YTD
-34.51%
-34.51%
1 Month
+13.11%
+13.11%
3 Month
+4.29%
+4.29%
6 Month
+15.17%
+15.17%
1 Year
-36.91%
-36.91%

More News

Read More
Gold Down Over 3%; Rigetti Computing Shares Spike Higher
Via Benzinga
Crude Oil Down 3%; Chicago Fed National Activity Index Falls In October
Via Benzinga
Topics Economy
Exposures Fossil Fuels Interest Rates
BridgeBio Pharma, Rigetti Computing, Bath & Body Works And Other Big Stocks Moving Higher On Monday
Via Benzinga
BridgeBio Catapults After Snagging Approval For Pfizer-Rivaling Heart Drug
Via Investor's Business Daily
FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market
Via Benzinga
Exposures Product Safety
Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market
Via Benzinga
Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma Reports Third Quarter 2024 Financial Results and Business Update
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Announces Publication of Case Study Exploring Portfolio Theory’s Impact on Biomedical Innovation in The Journal of Portfolio Management
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene Therapy BBP-812 for Canavan Disease at ESGCT 2024
From BridgeBio Pharma, Inc.
Via GlobeNewswire
3 Top Stocks That Could Still Rocket Higher in 2024
Via The Motley Fool
BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma's Lead Candidate Cuts Mortality, Related Hospitalizations In Patients With Certain Type Of Heart Disease
Via Benzinga
Exposures Product Safety
BridgeBio Completes Enrollment of FORTIFY, Phase 3 Registrational Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, Demonstrating a 42% Reduction by Acoramidis on the Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular-related Hospitalization Events
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Announces Infigratinib Is the First Ever Investigational Therapeutic Option for Achondroplasia to Be Awarded Breakthrough Therapy Designation by the FDA
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma Seeks Partner To Develop Gene Therapy For Inherited Condition
Via Benzinga
BridgeBio Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for BBP-812 Canavan Disease Gene Therapy Program
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma Reports Topline Results from Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Patchy And Still Patchy In The Short Term
Via Talk Markets
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.